Recent Company News

• 10:15 PM ET Nov 04, 2025
  

  Teijin reports Q2 net income attributable (¥54.2B) vs year-ago (¥57.8B) (¥1303.0000, -36)

• 02:01 PM ET Oct 24, 2025
  

  StreetAccount Activist Summary: Week of 20-Oct

• 07:13 PM ET Oct 23, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Jul-Sep Earnings

• 10:11 PM ET Oct 22, 2025
  

  Teijin Pharma signs licensing agreement with Elevara Medicines for rheumatoid arthritis drug candidate TCK-276 (¥1364.5000, +9.5)

• 11:31 AM ET Oct 06, 2025
  

  Teijin releases 2025 Integrated Report (¥1309.0000, 0)

• 11:43 AM ET Sep 09, 2025
  

  Teijin releases Integrated Report 2025 (ESG pg.88) (¥1327.0000, 0)

• 06:06 AM ET Aug 29, 2025
  

  Teijin to transfer shares in DuPont Teijin Advanced Papers (Japan) Limited and DuPont Teijin Advanced Papers (Asia) Limited to DuPont de Nemours (¥1261.0000, 0)

• 02:36 AM ET Aug 25, 2025
  

  Teijin Pharma receives manufacturing and marketing approval in Japan for YORVIPATH as treatment for hypoparathyroidism (¥1286.0000, 0)

• 03:35 AM ET Aug 07, 2025
  

  Teijin unit Teijin Aramid reports yesterday's fire at Delfzijl plant in the Netherlands (¥1294.0000, 0)

• 10:35 PM ET Aug 04, 2025
  

  Teijin reports Q1 net income attributable (¥740M) vs FactSet ¥5.40B [2 est, ¥4.30-6.50B] (¥1315.5000, +20.5)